Published in

BMJ Publishing Group, International Journal of Gynecological Cancer, 2(15), p. 319-324, 2005

DOI: 10.1136/ijgc-00009577-200503000-00022

BMJ Publishing Group, International Journal of Gynecological Cancer, 2(15), p. 319-324

DOI: 10.1111/j.1525-1438.2005.15223.x

Links

Tools

Export citation

Search in Google Scholar

Total laparoscopic hysterectomy versus total abdominal hysterectomy for obese women with endometrial cancer

Journal article published in 2005 by A. Obermair ORCID, T. P. Manolitsas, Y. Leung, I. G. Hammond, A. J. McCartney
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Obesity is common in endometrial cancer and surgery for these patients is challenging. We compared total laparoscopic hysterectomy (TLH) with total abdominal hysterectomy (TAH) with respect to feasibility (operating time, estimated blood loss, length of hospital stay, and conversion to laparotomy) and safety (perioperative morbidity and mortality) in a retrospective analysis of 78 morbidly obese patients with endometrial cancer. Analysis is based on the intention to treat. The intention to treat was TLH in 47 patients and it could be successfully completed in 42 patients (89.4%). The mean weight for all patients was 118.7 kg, with patients in the TLH group weighing more and having higher ASA scores. Mean operating time and estimated blood loss were similar in both groups. Mean postoperative hospital stay was 4.4 (±3.9) days in the TLH group and 7.9 (±3.0) days in the TAH group (P < 0.0001). Wound infections occurred in 15 of 31 patients (48.4%) in the TAH group and in 1 of 47 patients (2.1%) in the TLH group. All other morbidity, as well as patterns of recurrence and survival were similar in both groups. These data justify a prospective randomized trial comparing TLH with TAH for the treatment of endometrial cancer